許 翰琳

Medicine & Life Sciences

1. ErbB Receptors 100%
2. Taiwan 79%
3. Esophageal Squamous Cell Carcinoma 74%
4. Chemoradiotherapy 73%
5. Adenocarcinoma of Lung 64%
6. Lung Neoplasms 58%
7. Thorax 54%
8. Non-Small Cell Lung Carcinoma 47%
9. Intensity-Modulated Radiotherapy 43%
10. Radiotherapy 41%
11. Tuberculosis 38%
12. Multidrug-Resistant Tuberculosis 38%
13. Confidence Intervals 35%
14. Beijing 30%
15. Cisplatin 30%
16. Protein-Tyrosine Kinases 30%
17. Prothionamide 27%
18. Mycobacterium tuberculosis 26%
19. Case-Control Studies 25%
20. Acinetobacter calcoaceticus 24%
21. Annexin A2 23%
22. Genotype 22%
23. Corneal Topography 21%
24. Treatment Adherence and Compliance 21%
25. Pterygium 21%
26. Conformal Radiotherapy 21%
27. Annexins 21%
28. Refractive Surgical Procedures 20%
29. Immunoglobulin Domains 20%
30. Latent Tuberculosis 20%
31. Uridine Diphosphate 20%
32. Pulmonary Tuberculosis 20%
33. Aryl Hydrocarbon Receptors 20%
34. Survival 20%
35. Hypoxia-Inducible Factor 1 19%
36. Small Cell Lung Carcinoma 19%
37. Circulating Neoplastic Cells 19%
38. Acinetobacter baumannii 19%
39. Privacy 18%
40. Astigmatism 18%
41. Esophagectomy 18%
42. Chloramphenicol 17%
43. Angiotensin Receptor Antagonists 17%
44. Carboplatin 17%
45. Oncogene Proteins 17%
46. Time-to-Treatment 17%
47. Mortality 16%
48. Bacteremia 16%
49. Cell Movement 15%
50. Angiotensin-Converting Enzyme Inhibitors 15%